한글목차

본 보고서는 의약품 및 바이오테크놀러지 분야의 자산구매 거래 동향을 조사하고, 기업이 사업, 제품, 기술, 로열티 자산구매 거래를 하는 방식과 이유를 자세히 이해하고 분석합니다.

이 보고서는 당사자 간에 발표된 자산구매 거래의 지불 조건에 대한 액세스를 제공합니다. 이 데이터를 통해 지불 조건 및 기타 거래 조건에 대한 유용한 인사이트를 얻을 수 있습니다.

본 보고서에서는 구매 가능한 4가지 주요 자산에 초점을 맞추고 있습니다:

• 사업 자산
• 제품 자산
• 로열티 자산
• 기술 자산

주요 장점:

본 보고서는 다음과 같은 주요 이점을 제공합니다:

• 2019년 이후 거래 동향을 파악할 수 있습니다.
• 자산구매 거래 열람 가능
• 벤치마크 분석 - 거래의 시장 가치를 파악할 수 있습니다.
• 재무 - 헤드 라인, 계약 일시금, 마일스톤, 로열티 비율을 확인할 수 있습니다.
• 기업(A-Z), 치료 분야, 기술 유형별 거래 디렉토리를 확인할 수 있습니다.
• 주요 거래금액을 확인할 수 있습니다.
• 가장 활발한 거래 업체를 확인할 수 있습니다.
• 각 거래의 자산과 거래 조건을 확인할 수 있습니다.
• 계약 문서에 대한 액세스 - 거래 구조에 대한 인사이트 제공
• 실사 - 제안된 거래 조건이 파트너사에 적합한지 평가할 수 있습니다.
• 수백 시간의 조사 시간을 절약할 수 있습니다

조사 범위:

• 생명과학 산업의 자산구매 거래 동향
• 자산구매 거래 구조 개요
• 의약품, 바이오테크놀러지, 의료기기, 진단약 등 자산구매 거래기록을 다루는 자산구매 거래기록 디렉토리
• 주요 자산구매 거래
• 가장 활발한 자산구매 거래 업체
• 주요 자산구매 파트너 정보

목차

주요 요약

제1장 소개

제2장 자산구매 거래 동향

• 구입한 자산 종류
• 2019년 이후 자산구매 거래 동향
  • 자산구매 거래 동향 : 연도별
  • 자산구매 거래 : 개발 단계별
  • 자산구매 거래 : 산업 부문별
  • 자산구매 거래 : 치료 분야별
  • 자산구매 거래 : 기술 유형별
  • 자산구매 거래 : 가장 활발한 기업
• 자산구매 제휴 계약을 체결하는 이유
  • 사업 자산
  • 제품 자산
  • 로열티 자산
  • 기술 자산
• 자산구매 거래의 미래

제3장 자산구매 거래 구조 : 개요

• 자산구매 거래 구조

제4장 주요 자산구매 거래

• 상위 자산구매 거래 : 금액별

제5장 가장 활발한 자산구매 거래 제조업체 상위 25개사

• 가장 활발한 자산구매 거래 제조업체 상위 25개사

제6장 계약 디렉토리를 포함한 자산구매 거래

• 2019년에서 2025년까지 계약·자산구매 거래
• 거래 디렉토리
• 거래 디렉토리 자산구매 거래 : 기업별(A-Z)
• 거래 디렉토리 자산구매 거래 : 치료 분야별
• 거래 디렉토리 자산구매 거래 : 기술 유형별
• Biopharma Research Ltd에 대해
• 현재 제휴
• 현재 계약
• Current Partnering에서의 최근 보고서 제목

영문목차

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year, 2019-2025
  • 2.3.2. Asset purchase dealmaking by phase of development, 2019-2025
  • 2.3.3. Asset purchase dealmaking by industry sector, 2019-2025
  • 2.3.4. Asset purchase dealmaking by therapy area, 2019-2025
  • 2.3.5. Asset purchase dealmaking by technology type, 2019-2025
  • 2.3.6. Asset purchase dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2019-2025
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2019-2025
• Figure 3: Asset purchase deals signed at each phase of development, 2019-2025
• Figure 4: Asset purchase deals by industry sector, 2019-2025
• Figure 5: Asset purchase deals by therapy area, 2019-2025
• Figure 6: Asset purchase deals by technology type, 2019-2025
• Figure 7: Top 25 most active asset purchase dealmakers, 2019-2025
• Figure 8: Top asset purchase deals by value, 2019-2025
• Figure 9: Most active asset purchase dealmakers, 2019-2025